NASDAQ
ADVB
Last Price
US $5.09
KEY FIGURES
MKT CAP
$5.5M
EPS
TTM
$-0.53
PEG
TTM
-
P/E
TTM
N/M
P/S
TTM
-
YIELD
0.00%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
-65.06%
Return on equity
ROIC: 280.22%
Valuation History
-24.2X
Price to Earnings
EV/EBITDA: -3.7X
Cash flow
Profit margin
-
(FY vs FY)
EBITDA Y/Y
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $5.09
—
Default assumptions
EBITDA Multiple
Fair Value
Market $5.09
52599.02%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Advanced Biomed Inc. Common Stock cash flow to debt ratio of -14.35% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
Advanced Biomed Inc. Common Stock's free cash flow has increased -91.71% from $-2.20M last year to $-182.45K, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
Advanced Biomed Inc. Common Stock's debt to equity ratio is 2.47, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
Advanced Biomed Inc. Common Stock's debt has increased relative to shareholder equity from 0.08 last year to 2.47 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Advanced Biomed Inc. Common Stock has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Advanced Biomed Inc. Common Stock earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Advanced Biomed Inc. Common Stock has insufficient data to evaluate this check.
Financial stability - Short term assets vs short term liabilities.
Advanced Biomed Inc. Common Stock's short-term assets of $6.03M exceed its short-term liabilities of $2.89M
Decreasing performance - ROA.
Advanced Biomed Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Advanced Biomed Inc. Common Stock's return on equity of -65.06%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Advanced Biomed Inc. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Advanced Biomed Inc. Common Stock had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Advanced Biomed Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Advanced Biomed Inc. Common Stock has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Advanced Biomed Inc. Common Stock's yearly earnings has increased -96.35% since last year from $-2.78M to $-101.52K, signaling increasing performance
Increasing performance - Healthy revenue growth.
Advanced Biomed Inc. Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Increasing performance - ROIC.
ROIC 280.22% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Decreasing performance - 3-year revenue CAGR.
Advanced Biomed Inc. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Advanced Biomed Inc. Common Stock had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Advanced Biomed Inc. Common Stock had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Advanced Biomed Inc. Common Stock has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Advanced Biomed Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - EBITDA valuation.
Advanced Biomed Inc. Common Stock is undervalued relative to its fair value price of 2.68K based on EBITDA multiple model
Overvalued - EV/EBITDA.
Advanced Biomed Inc. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Advanced Biomed Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Advanced Biomed Inc. Common Stock has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
Advanced Biomed Inc. Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue